<DOC>
	<DOC>NCT01274663</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-05175157 in healthy volunteers.</brief_summary>
	<brief_title>A Study Of PF-05175157 In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy male and/or female (non childbearing potential) subjects between the ages of 18 and 45 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12lead ECG and clinical laboratory tests. In addition, subjects must have normal chest xray, normal pulmonary function tests and normal ophthalmological examination. Body Mass Index (BMI) of 17.5 to 29.5 kg/m2; and a total body weight &gt; 50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies). Evidence or history of any chronic ongoing or current pulmonary disease. History of smoking in the past 5 years or history or evidence of habitual use of other (nonsmoked) tobacco or nicotinecontaining products within 3 months of Screening or positive cotinine test at Screening or Day 0. Active ocular disease including infection, glaucoma, seasonal allergies, dryeye symptoms or retinal/optic nerve disease. Evidence or history of 'dry eyesyndrome', Meibomian gland disease, ocular inflammation (eg, uveitis, iritis), chronic blepharitis, any eye surgery including Lasik, any mechanical injury or chemical exposure to the ocular surface, use of ocular lubricants, or use of contact lenses.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Safety and Tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>